Current research into retatrutide peptide reveal significant potential for managing weight and non-insulin dependent disease. The compound, a dual stimulator of glucagon-like peptide-1 and GIP, seems to offer greater weight reduction and glucose control compared existing medications. Ongoing patient studies are needed to thoroughly evaluate its wel